TY - JOUR
T1 - Perspectives on treatment of metastatic castration-resistant prostate cancer
AU - Merseburger, Axel S.
AU - Bellmunt, Joaquim
AU - Jenkins, Cheryl
AU - Parker, Chris
AU - Fitzpatrick, John M.
N1 - Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2013/5
Y1 - 2013/5
N2 - The arrival of several new agents-cabazitaxel, abiraterone acetate, enzalutamide, and radium-223-is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.
AB - The arrival of several new agents-cabazitaxel, abiraterone acetate, enzalutamide, and radium-223-is changing the treatment options and management of patients with metastatic castration-resistant prostate cancer (mCRPC). Many other novel agents are also being investigated. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. This review article is a summary of a European Treatment Practices Meeting, which was convened to discuss these latest data on novel agents and current treatment strategies in the mCRPC setting.
UR - http://www.scopus.com/inward/record.url?scp=84878198393&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2012-0478
DO - 10.1634/theoncologist.2012-0478
M3 - Journal articles
C2 - 23671006
AN - SCOPUS:84878198393
SN - 1083-7159
VL - 18
SP - 558
EP - 567
JO - Oncologist
JF - Oncologist
IS - 5
ER -